Sellas Life Sciences Group Inc (SLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2016 | 03-2016 | 12-2015 | 09-2015 | 06-2015 | |
| Operating Expenses | 9,292 | 8,968 | 7,590 | 8,635 | 9,083 |
| Operating Income | -9,292 | -8,968 | -7,590 | -8,635 | -9,083 |
| Interest Expense | 519 | 91 | 602 | 158 | 0 |
| Other Income | 18,089 | -4,043 | -2,267 | 2,441 | -4,391 |
| Pre-tax Income | 8,278 | -13,102 | -10,459 | -6,352 | -13,474 |
| Net Income Continuous | 8,278 | -13,102 | -10,824 | -6,352 | -13,474 |
| Net Income Discontinuous | -2,889 | -3,391 | -8,855 | -11,674 | -2,186 |
| Net Income | $5,389 | $-16,493 | $-19,679 | $-18,026 | $-15,660 |
| EPS Basic Total Ops | 885.89 | -2,762.76 | -3,648.65 | -3,303.30 | -3,003.00 |
| EPS Basic Continuous Ops | 1,366.37 | -2,192.19 | -2,132.13 | -1,201.20 | -2,402.40 |
| EPS Basic Discontinuous Ops | -480.48 | -570.57 | -1,516.52 | -2,102.10 | -600.60 |
| EPS Diluted Total Ops | 870.87 | -2,762.76 | -3,648.65 | -3,303.30 | -3,003.00 |
| EPS Diluted Continuous Ops | 1,351.35 | -2,192.19 | -2,132.13 | -1,201.20 | -2,402.40 |
| EPS Diluted Discontinuous Ops | -480.48 | -570.57 | -1,516.52 | -2,102.10 | -600.60 |
| EBITDA(a) | $-9,233 | $-8,962 | $-7,787 | $-8,512 | $-9,000 |